Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
just realistic. the MM's are very transparent. when they fill a lot on the bid when the ask is a few pennies higher, they know they will be dropping the stock later that day or days to follow. this pig is going down into the close - unfortunately
It’s more fun seeing the stock actively rise a tick at a time but this is fantastic consolidation for the next step up. Call this acclimating at base Camp 2, getting ready for the climb to Camp 3.
U sound like a person that wants it to drop, not like a person whom just bought shares
ugly trading action. you can tell the market is fed up with IPIX delays and lack of news
About to move up.
I purchased 2200 at 12:11:14, so I am dubious about what u say
Don’t believe that for a second. Go IPIX.
the 3548 buy was mine at $1. this pig is heading lower. watch that 1.03 ask crumble
When the pack stars biting each other’s tail I think a big upward movement is imminent
With both PhII trials ended, if Leo was in talks with a BP over one of the drugs, would trial results be allowed to be shared for the other drug while the talks were ongoing?
If my words speak for themselves, then you shouldn’t have a problem posting all of them instead of cherrypicking.
To answer your question, of course it’s a fail. Not meeting primary endpoints is universally considered failing a trial. People can spin otherwise according to their book.
I agree the fda and pharma matter. If ipix fails to meet primary endpoints, the fda woukd not permit ipix to run a phase 3. Pharma would not give ipix a good deal.
Case closed.
almost a 100% upside for me!... love to see it, but would not sell it when likely see 5x $1.58 within 6 months.
What I see is every indication for successful outcomes, all outcomes! Please point to any signal for possible failure:
“Cellceutix is encouraged by the interim data from the OM trial (a double blind, placebo controlled study), given the fact that there are no FDA-approved drugs for the prevention of OM in the study population. According to the preliminary interim results from the trial, only 2 of 9 patients (22.2%) on Brilacidin-OM therapy developed severe OM, defined as Grade 3 or Grade 4 on the World Health Organization (WHO) OM Grading Scale. Patients in the placebo-treated control arm developed severe OM at a much higher rate, with 7 of 10 patients (70%) progressing to that condition. There are now an additional 11 patients active in the trial and more are added weekly.”
...it is very apparent that majority of shareholders are long term...therefore the float in reality is much smaller...and shorts are at dire risk of positive headlines on phase 2 results.
Your posts are indeed hyperbolic. They do indeed seem designed to raise unreasonable fear. On the one hand they say you think OM will be successful, yet within moments another post states how it is all or none and the dire consequences of failure. It’s a contradiction. Contradiction is not fair and balanced if it fails to outline the elements of failure and the real chances of such failure. Knowing the results of interim data, highly successful results (not just signals), why are the posts putting such high emphasis on failure? Repeatedly!
gonna sell some IPIX right here at 1.05. bought earlier at 1. that's 5% in an hour
your words speak for themselves, so they should stand
people can/should easily click on folk's posting history, imo, to get a feel for their, ahem, positions
as to failing ? so say B-OM primary is not met but secondary ends up kicking A, performing better than any other OM trial data to date... is this a Fail?
market might initially not like the "primary not met" PR
but the people who really count are the FDA, the Pharma, who know the current S of C, the HUGE unmet need
that's what ultimately would matter all IMHO
You are omitting key parts of the discussion.
Regardless, I totally stand by my statement that failing to meet primary endpoints would be devastating for ipix. As per the link bio posted, compelling secondary endpoints are not enough to move into phase 3 or get fda drug approval.
Not meeting primary endpoints would mean FAILING the trial. IPIX cannot afford to FAIL a Brilacidin trial. I understand that you think that other trials are looking at duration, and that somehow that fact would make FAILING a trial ok. But you need to look at the real world and not only THE SCIENCE. In the real world, a big pharma will let ipix bleed and bleed after a TRIAL FAILURE. Ipix would be lucky to get pennies on the dollar at that point.
Case closed.
for reals now - i simply linked to / cut-paste my response to a post of yours ---- primary imo will be met and moreover, shored up with secondary/exploratory endpoints
what you fail to understand is that most other OM drugs in trial are going after Duration / Onset not Incident as primary
so by def IPIX could fail its primary (Incidence) but still perform well as others in the secondary (Onset, Duration)
market might care (prob though because it might not understand as well as some of us IPIX trial design), but FDA sure wouldn't care which is Primary, which is Secondary --
it'll all come down the FULL dataset ... Incidence, Onset, Duration... plus all the other measures
case closed
B-OM data expected any day. It wasn't a very large trial since the design was just to better nail down the WHO grade.
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: Phase 2 Study to Evaluate the Efficacy & Safety of Brilacidin Oral Rinse Administered Daily for 7 Weeks in Attenuating Oral Mucositis in Patients With Head & Neck Cancer Receiving Chemoradiation
Trial link...
https://clinicaltrials.gov/ct2/show/NCT02324335?term=cellceutix&rank=3
A couple blog articles...
https://www.ipharminc.com/new-blog/2017/11/21/brilacidin-as-a-successful-example-of-de-novo-drug-design
https://www.ipharminc.com/new-blog/2017/10/17/the-market-opportunity-in-oral-mucositis
Putting the word out to more of my followers. Getting closer and closer.
Nice consolidation from the .60/.70's.
Could very well grow some nice legs!
$IPIX
The only part of this that I would agree with you on is the O/M top line trial results.
Thanks, Paul
C, there are those that haven’t done any due diligence prior to buying who are much more susceptible to the influential postings on a forum...
...then there’s the rest of us who studied CTIX/IPIX years ago prior to loading in the .50s, and for which the science has continued to progress in an outstanding fashion.
For the second group, the Mako attacks were seen as nothing more than an excellent buying opportunity. The fear mongering for me just sparks the thought “wonder how low they can ‘fear’ push this? And where are the buying supports I should ADD MORE IPIX.”
Cheers brother.
im just laying out what was discussed, ad infinitum, over the weekend -- that reducing (preventing) Incidence of severe OM (what IPIX Is targeting) is entirely different than reducing (lowering) Duration or Onset of severe OM
very easy for folks to go back and see how that Chat shook out -- a few clicks worth of work -- and come to their own conclusions who was being more fair and balanced
You should really post the whole thread, otherwise it appears you are cherry picking pieces of a conversation to make your point. And I KNOW that’s not your intention.
Huh?
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=136609956
Your Hyperbolic words in response to biodoc:
“But what you write really has no practical application for ipix. Primary endpoint failure would be devastating. There’d be no second chances.”
So that IPIX’s main Secondary outcome (Duration) is what most other Rx are using as their Primary — not Incidence, like us — isn’t relevant???
Other Rx in fact are saying Duration **is good enough** to get approved and this with Regulatory input (eg SGNX Ph 3 trial design)
Your logic: Does. Not. Compute.
As to B-OM, I do expect a Reduction in Incidence (Primary) vs placebo and Reduction in Duration (Secondary)
how great the spread need be in Primary?
Anything over 10pt imo a success.
Anything over 20pt imo Big Success.
Anything over 30pt imo HUGE.
Again there is no approved OM treatment out there other than KEPIVANCE, with limited label, recently pulled from Europe. OM doubles cost of care and results in 20% dying prematurely from what I recall reading.
So enough w the dire language — “failure” “devastating” “no second chances”
B OM has BTD potential and the FDA and any Rx Partner will see that if Topline delivers a successful trial.
Again our Secondary - Reduction in Duration - is other Rxs Primary... on its own, RID might elicit approval regardless of RII, highest bar
Sorry! I know I’m a real ipix influencer. I will try to be more careful with my wording from now on.
That's not what your response to Dunn said. You specifically said results have to be very good or great or IPIX will see the .70's again. You forgot to mention that you are expecting outstanding results etc., and they will put $1.00 behind us forever.
I'm going to sue you for the unauthorized use of my photo. SpongeBob, Out
NO, NO! NOT The SQUEEZE! :O)
Talking what down? I’m expecting outstanding OM results early next week. That will put 1.00 behind us forever.
ROFLMAO at the fear mongering and doom spreaders.
After 6 days above the upper bb, price starts moving back inside while indicators cool and all of a sudden the sky is falling. LOL
Never know, it could turn into a bull flag.....heehee
Hilarious that posters would puke such nonsense all over the board with news expected. Positive news at that.
IPIX
I know I'm ready for take off. Anticipation!!!
Bring on the data!! Partnerships!!!!
$IPIX
Talking them down again Smith?
I shorted at .68 will cover 1.5-2.00. I feel like I am going to get short squeezed.
heading under a dollar. My junk bid at $1 just filled when the ask was 1.02.
we might see .93 or worse today
IPIX is NOT a POS!!! Dude... clinical trial results are due ANY DAY NOW, and are widely expected to be very positive! And it's also expected that good results will spark intensified big pharma deal making for use cases or one of the company's three separate drug platforms. THIS COMPANY IS NOT A POS!!! It's a potential rocket ship.
Further, price action now has nothing to do with that of March, because we are in a MUCH more favorable position now than we were then!
DOTB
I'll pay you $10 right now to retire!
Dude. NO!!! THERE'S NO "BUYOUT ZONE" except the one that you make-up in your own head!
The actual buy out price for IPIX would be $50 or greater, depending on future clinical trial results and BP interest. Not 90 cents, not $1, not $1.12. No, FIFTY DOLLARS OR GREATER!!!!!!!
DOTB
Maybe a 5 percent chance we see K results this quarter. And a 95 percent chance OM results come out next week. OM results need to be very good to great or ipix will see the .70s fast.
Two good reports could occur.
Echo20
No Gap. No Crap. All good. Going much higher.
gap and crap just as I predicted. this POS is setting the same pattern that it did in March
Leo's deadline is December 31st... This includes K interim... Not a surprise to see Leo use up the entire month or quarter for any forecast. P will shift to Q1 completion or results.
like I said if a trader is going to sell before the news because they can't wait a week or even 2 weeks, they were just going to sell after the news anyway. It would have averaged out in the end.
Those aren't the ones that are going to take the stock higher. So who cares when they sell.
Lol really. Never thought? Come on. Though the volume on the way down is far less than on the way up. For now. Good news is everyone knows results are early next week. Shouldn’t see too much dumping. But God help us all if results aren’t out by Tuesday.
We'll see if 1 holds, never thought we'd go back under 1 again, but this is IPIX.
Shorted at .68. Will cover at 2.00. I love short squeezes.
Red on the day like I predicted. another feeble gap and crap
TD it’s gonna be a good day. I am looking forward to next week.
here comes the selling. ask down to 1.06. This will see around $1 again today. OBV looks awful
Followers
|
974
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
403648
|
Created
|
05/10/08
|
Type
|
Free
|
Moderators zandant sunspotter snayeman loanranger frenchbroad |
Innovation Pharmaceuticals Inc. (IPIX)
$IPIX NEWS - http://ipharminc.com/press-release
SEC Filings https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
From the most recent 10-K:
There are doubts about our ability to continue as a going concern.
We have generated revenue of $0 and $18,000 for the fiscal years ended June 30, 2023 and 2022, respectively and have an accumulated deficit of $125.3 million through June 30, 2023. These factors raise substantial doubt about our ability to continue as a going concern.
We need to raise substantial additional capital in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms, which could prevent us from fully implementing our business, operating and development plans.
We currently have an approximate $1.0 million cash balance as of the date of this filing, but that is insufficient to complete the development and commercialization of any of our proposed products. We expect to incur costs of approximately $1.8 million in the upcoming fiscal year ending June 30, 2024 to operate our business in accordance with our business plans and budgets.
We have limited experience in drug and formulation development, the conduct of clinical trials, and may not be able to successfully develop any drugs.
Development of pharmaceutical products is a risky and time-consuming process subject to a number of factors, many of which are outside of our control. We are subject to regulatory authority permissions and approvals, most importantly the FDA. Our drug candidate(s)/indications are at early and mid-stages of development. Consequently, we can provide no assurance of the successful and timely development of new drugs, and the failure to do so could cause us to cease operations.
We may elect to deregister our common stock under the Exchange Act and suspend our reporting obligations. Such deregistration and suspension would result in less disclosure about us and may negatively affect the liquidity and trading prices of our common stock.
http://www.ipharminc.com/
About Innovation Pharmaceuticals Inc.:
Established in 2007, and headquartered in Wakefield, Massachusetts, Innovation Pharmaceuticals Inc. (formerly Cellceutix Corporation) is a publicly traded biopharmaceutical company dedicated to discovering and advancing innovative medical therapies with dermatology, oncology, anti-inflammatory and antibiotic applications.
Through ongoing research and drug development efforts, Innovation is focused on improving the clinical care of patients, as well as growing shareholder value. Our team consists of a diverse and accomplished group of professionals working together toward achieving this common goal.
IPIX CEO - "The Company historically devoted most of its efforts and resources on business development, regulatory matters, and clinical trials. Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully." "In general, we expect to concentrate on product development and engage in a limited way in product discovery, avoiding the significant investment of time and financial resources that is generally required for a promising compound to be identified and brought into clinical trials." Source - https://www.sec.gov/ix?doc=/Archives/edgar/data/1355250/000147793223003414/ipix_10q.htm
More information is available at http://www.ipharminc.com.
Management: http://www.ipharminc.com/senior-management/
Scientific Advisors: http://www.ipharminc.com/scientific-advisors/
Clinical Trials: https://clinicaltrials.gov/ct2/results?cond=&term=%22Innovation+Pharmaceuticals%2C+Inc.%22++&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps
Trials under previous name: https://clinicaltrials.gov/ct2/results?cond=&term=cellceutix&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps
Product Pipeline: http://www.ipharminc.com/therapeutic-areas/
Recent News and Press Releases:
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/
SEC Filings (CIK:0001355250): https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com
Share Structure: See SEC filing link above for current share structure
Investor Relations:
http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1
Chart: https://stockcharts.com/h-sc/ui?s=IPIX
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |